The DOI matches its Crossref record.
Population differences in S‐warfarin metabolism between CYP2C9 genotype‐matched Caucasian and Japanese patients
Abstract
Objective: Our objective was to investigate population differences in the metabolic activity of cytochrome P450 (CYP) 2C9 between genotypically matched Caucasian and Japanese patients by using the unbound oral clearance of S‐warfarin as an in vivo phenotypic trait measure. Methods: Ninety Japanese and 47 Caucasian patients receiving maintenance warfarin therapy were studied. Steady‐state plasma unbound concentrations of S‐warfarin were measured by a chiral HPLC method coupled with an ultrafiltration technique, and unbound oral clearance for S‐warfarin was estimated. By combining plasma unbound concentrations of S‐warfarin with the urinary excretion rates of S‐7‐hydroxywarfarin, the formation clearance of S‐7‐hydroxywarfarin was also determined. Genotyping of CYP2C9 was performed for 6 distinct alleles (CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, and a T/C transition in intron 2). Results: The frequency distribution of unbound oral clearance for S‐warfarin obtained from Japanese patients was shifted toward higher values as compared with that in Caucasian patients. Japanese patients had lower allelic frequencies for the 5 variants than Caucasian patients. When interpopulation comparisons of CYP2C9 activity were made for genotype‐matched subjects, Japanese patients with the homozygous CYP2C9*1 (wild‐type) genotype (n = 85) had significantly (P < .01) greater median values for unbound oral clearance and formation clearance than Caucasian patients with the corresponding genotype (n = 26), 10.4 mL × min−1 × kg−1 versus 4.25 mL × min−1 × kg−1 and 0.015 mL × min−1 × kg−1 versus 0.010 mL × min−1 × kg−1, respectively. In addition, Japanese patients heterozygous for the CYP2C9*3 genotype (n = 4) showed a significantly (P < .05) reduced unbound oral clearance for S‐warfarin, by 63%, as compared with Japanese patients possessing the homozygous CYP2C9*1 genotype. By contrast, in Caucasian patients, no significant differences were observed in this parameter between CYP2C9*1 homozygous subjects and those with heterozygous CYP2C9*2 or CYP2C9*3 genotypes. Conclusions: These findings indicate that population differences in the frequencies of known variant CYP2C9 alleles account only in part for the variability observed in in vivo CYP2C9 activity in different populations. In addition, a gene‐dose effect of defective CYP2C9 alleles on the in vivo CYP2C9 activity is evident in Japanese patients but not in Caucasian patients. Further studies are required to identify currently unknown factor(s) (eg, transcriptional regulation) responsible for the large intrapopulation and interpopulation variability in CYP2C9 activity. Clinical Pharmacology & Therapeutics (2003) 73, 253–263; doi: 10.1067/mcp.2003.26
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Shen, A. Y.-J., Yao, J. F., Brar, S. S., Jorgensen, M. B., & Chen, W. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.098 · Cited by 656
Shimada, T. (2006) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.21.257 · Cited by 606
Cruz-Flores, S., Rabinstein, A., Biller, J., Elkind, M. S. V., Griffith, P., Gorelick, P. B., Howard, G., Leira, E. C., Morgenstern, L. B., Ovbiagele, B., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182213e24 · Cited by 507
Yuan, H.-Y., Chen, J.-J., Lee, M. T. M., Wung, J.-C., Chen, Y.-F., Charng, M.-J., Lu, M.-J., Hung, C.-R., Wei, C.-Y., Chen, C.-H., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi180 · Cited by 486
Clinical consequences of cytochrome P450 2C9 polymorphisms
KIRCHHEINER, J., & BROCKMOLLER, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.009 · Cited by 474
Takahashi, H., Wilkinson, G. R., Nutescu, E. A., Morita, T., Ritchie, M. D., Scordo, M. G., Pengo, V., Barban, M., Padrini, R., Ieiri, I., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000184955.08453.a8 · Cited by 376
Self-citationCYP2C9 allelic variants: ethnic distribution and functional significance
Xie, H.-G., Prasad, H. C., Kim, R. B., & Stein, C. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00076-5 · Cited by 338
Self-citationStroke prevention in atrial fibrillation: An Asian perspective
Wang, K.-L., Lip, G. Y. H., & Chiang, C.-E. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-11-0948 · Cited by 287
CLINICAL AND TOXICOLOGICAL RELEVANCE OF CYP2C9: Drug-Drug Interactions and Pharmacogenetics
Rettie, A. E., & Jones, J. P. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095821 · Cited by 254
Rosuvastatin safety: lessons from the FDA review and post-approval surveillance
Davidson, M. H. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.6.547 · Cited by 80
Metadata
- Authors
- Takahashi, H., Wilkinson, G. R., Caraco, Y., Muszkat, M., Kim, R. B., Kashima, T., Kimura, S., & Echizen, H.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2003-03
- Volume
- 73
- Issue
- 3
- Pages
- 253-263
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2144867854
- Cited by
- 190
- References
- 0
- FWCI
- 14.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.